Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus docetaxel versus sequential trastuzumab then docetaxel in first-line HER2-positive metastatic breast cancer
NL-OMON26229Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Feb 2003
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of trastuzumab and docetaxel in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-free survival. Started Feb 2003; status: active, not recruiting.
02
Drugs
trastuzumabdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON26229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26229.